POZEN (POZN) Slammed as FDA May Limit PA32540 Treatment in Post-CABG Patients
Go back to POZEN (POZN) Slammed as FDA May Limit PA32540 Treatment in Post-CABG Patients| Pozen, Inc. (NASDAQ: POZN) | Delayed: 5.94 --0 (-0%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $5.94 | 52 Week High | $12.69 | |||
| Open | $4.62 | 52 Week Low | $5.49 | |||
| Day High | $5.94 | P/E | N/A | |||
| Day Low | $5.94 | EPS | $-0.68 | |||
| Volume | 397,966 | |||||
